VISCOGEL AB REPORTS POSITIVE RESULTS FROM SAFETY STUDIES

Viscogel AB today announced a successful completion of the toxicology studies that were carried out within the ViVac-project. The results showed that ViscoGel® was well tolerated even at higher doses and no unexpected effects were observed.The recent toxicology studies were completed in order to prepare for the planned clinical trial with the company’s vaccine adjuvant, ViscoGel®. The toxicology results were included in the recently submitted regulatory application to start a clinical phase I/II study in Sweden. The clinical trial will evaluate safety and efficacy of ViscoGel® in